Test Price
900 AED✅ Home Collection Available
Culture-Based AFB Antitubercular Drug Susceptibility Testing (DST) Rapid 4-Drug Panel in UAE | 900 AED | DHA Approved
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: Paid hospital-grade specimen transport via ISO certified cold-chain courier; mobile phlebotomy is not applicable for this culture-based assay.
- Clinical Guidance: Telephonic post-test clinical guidance in result interpretation from a DHA-licensed physician.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced microbiology assay determines the in vitro susceptibility of cultured Mycobacterium tuberculosis complex to four first-line anti-tuberculosis agents: Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide, using an automated fluorescent detection system for rapid, reliable results. Ideal for guiding personalized treatment plans and detecting multidrug-resistant TB (MDR-TB), this test supports UAE’s TB elimination goals under DHA protocols.
| Feature | Our Test (DST Rapid 4-Drug Panel) | Closest Alternative (Conventional Solid Media) |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity (Automated Fluorescent) | Approx. 85–90% Sensitivity (Proportion Method) |
| Methodology | BACTEC MGIT 960 Automated Fluorescent Detection | Löwenstein-Jensen (LJ) Solid Media Proportion Method |
| Turnaround Time | 21 Days from Pure Culture | 28–42 Days |
| Drug Panel | INH, RIF, EMB, PZA (Standardized Critical Concentrations) | INH, RIF, EMB (PZA less reliable on solid media) |
| Standardization | WHO Endorsed, DHA/MOHAP Compliant | Traditional, Less Stringent QC |
Physician Insight & Safety Protocols
“As a DHA-licensed general practitioner, I stress that this drug susceptibility panel must be interpreted alongside the patient’s clinical history, radiographic findings, and prior treatment exposure. The phenotypic data guides the construction of an effective antitubercular regimen but should never be used in isolation. Do not discontinue prescribed medications without consulting your doctor.”
— Dr. Ajay Singh, General Practitioner | DHA Registration ID: 36234132
⚠️ Patient Safety & Advisory
- Exclusion Criteria: Inadequate specimen (mixed culture, non-viable bacteria, insufficient growth). Specimen not submitted in approved sterile container.
- Do Not Delay Therapy: If the patient exhibits severe or rapidly progressive tuberculosis, empirical therapy per DHA guidelines must commence; do not wait for DST results.
- ER Red Flags: Hemoptysis, severe respiratory distress, altered mental status, signs of disseminated TB (meningismus, spinal pain) – proceed immediately to the nearest emergency department.
- Minors: Sample collection from minors requires guardian consent and valid Emirates ID documentation.
- Do Not Stop Medications: Never discontinue any anti-tuberculosis drug without direct physician instruction.
Patient FAQ & Clinical Guidance
1. Why is this drug susceptibility test necessary for my tuberculosis treatment?
Drug susceptibility testing identifies whether Mycobacterium tuberculosis is resistant to first-line drugs, ensuring effective, tailored treatment and preventing the spread of multidrug-resistant TB.
2. How is the sample collected, and what do I need to do?
A pure culture of Mycobacterium tuberculosis complex is submitted in a sterile, screw-capped container under refrigerated transport to maintain viability for accurate testing. This culture is typically derived from a previous clinical specimen (e.g., sputum) processed in a hospital laboratory. No direct patient collection is required for this test phase.
3. What will the results tell my doctor, and how should I interpret them?
Results indicate whether each drug is 'susceptible' or 'resistant,' guiding the physician to prescribe a regimen that is most likely to cure the infection safely and minimize the risk of resistance development.
UAE Regulatory & Data Privacy Adherence
Legal and Privacy Compliance
This test and the associated laboratory procedures comply with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, and storage of patient health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating digital health records and telemedicine.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring clinical safety, informed consent, and professional accountability.
Our facility is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143. All patient data is encrypted, access-controlled, and never shared without explicit consent.
Clinical & Logistical Metadata
| Test Name | Culture-Based AFB Antitubercular Drug Susceptibility Testing (DST) Rapid 4-Drug Panel |
| Price (AED) | 900 |
| Turnaround Time | 21 days from pure culture receipt |
| Sample Type / Matrix | Pure culture of Mycobacterium tuberculosis complex |
| Methodology Used | BACTEC MGIT 960 Automated Fluorescent Detection |
| ICD-10-CM Code | Z01.89 |
| LOINC Code | 41683-7 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians